Products
Narlumosbart Biosimilar Monoclonal Antibody (RANKL) for Research
Cat No.: GMP-Bios-INN-1289
Anti-TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF therapeutic antibody (Pre-made Narlumosbart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Narlumosbart (development code JMT103) is a monoclonal antibody targeting RANKL (TNFSF11). It is developed by CSPC Pharmaceutical Group for hypercalcemia of malignancy and bone metastases. It is in Phase III clinical development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1289-1mg | 1mg | 3090 |
| GMP-Bios-INN-1289-10mg | 10mg | |
| GMP-Bios-INN-1289-100mg | 100mg | |
| GMP-Bios-INN-1289-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Narlumosbart biosimilar, Whole mAb, Anti-TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF Antibody: Anti-TNFSF11/RANKL/CD254/ODF therapeutic antibody |
| INN Name | Narlumosbart |
| Target | TNFSF11/CD254/RANKL/TRANCE/OPGL/ODF |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G4 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Approved |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | CSPC Pharmaceutical Group;Shanghai Jinmante Biotechnology |
| Conditions Approved | Giant cell tumour of bone |
| Conditions Active | Hypercalcemia of malignancy;Glucocorticoid-induced osteoporosis;Bone metastases from solid tumours |
| Conditions Discontinued | Malignant hypercalcaemia |
| Production | na |
| Development Tech | na |
